Redressing the Balance Against B Regulatory Cells: Novel Immunotherapeutic Target in Leishmaniasis
Parasite Immunology · 2025
DOI: 10.1111/pim.70024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Parasite Immunology, 2025. Verfasst von Sunil Kumar Dhatwalia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Zoology, Panjab University, Chandigarh, India. Hauptthemen laut MEDLINE: B-Lymphocytes, Regulatory, Leishmaniasis, Immunotherapy, Leishmania. Die Arbeit nennt 143 Literaturangaben. Gefördert von: Department of Science and Technology (DST) is a part of the Ministry of Science and Technology, Government of India.
Abstract (Originalsprache)
Leishmania parasite adeptly evades the host's immune defences by infiltrating macrophages, exploiting apoptotic processes for further dissemination. Among the host's strategies to counter parasitic propagation, the pivotal role of B‐cells, specifically B regulatory (Breg) cells, emerges. Recent evidence from in vitro and in vivo studies has thrust Breg cells into the spotlight, attributed to their IL‐10 secretion and antigen presentation. The escalated IL‐10 production coupled with decreased Th1 response provides a conducive milieu for parasitic proliferation within host cells. This abundance of IL‐10, from Breg cells and other immune sources, impedes T cell differentiation into Th1, Th2 and Th17 subsets. Moreover, IL‐10 obstructs CD8+ T cell differentiation into cytotoxic T cells, heightening the host's susceptibility to infections. Breg cells are also implicated in the production of IL‐35, which in turn mediates the conversion of B cells into Breg and IL‐35+ Breg cells and helps Leishmania to evade the immune response. Notably, recent data underscore the potential of B cell reprogramming via BTK and MEK inhibitors, offering a novel immunomodulation strategy. This approach presents a novel avenue for curbing Breg cells, potentially hindering prolonged BCR signalling. Although promising for Leishmania infection immunotherapy, a comprehensive understanding of IL‐10‐producing B cells' exact role demands further exploration. Developing targeted strategies to modulate Breg cell function could revolutionise Leishmania treatment, enhancing patient outcomes. Understanding Breg cells' role offers promising avenues for precise immunotherapy against this challenging infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Zoology, Panjab University, Chandigarh, India.
- Department of Biological Systems Engineering, Plaksha University, Mohali, Punjab, India.
Förderung
- Department of Science and Technology (DST) is a part of the Ministry of Science and Technology, Government of India
Zitieren
APA
Dhatwalia, S. K., Sharma, S., & Kaur, S. (2025). Redressing the Balance Against B Regulatory Cells: Novel Immunotherapeutic Target in Leishmaniasis. Parasite Immunology. https://doi.org/10.1111/pim.70024
Vancouver
Dhatwalia SK, Sharma S, Kaur S. Redressing the Balance Against B Regulatory Cells: Novel Immunotherapeutic Target in Leishmaniasis. Parasite Immunology. 2025. doi:10.1111/pim.70024
BibTeX
@article{Dhatwalia2025,
author = {Dhatwalia, Sunil Kumar and Sharma, Sheetal and Kaur, Sukhbir},
title = {Redressing the Balance Against B Regulatory Cells: Novel Immunotherapeutic Target in Leishmaniasis},
journal = {Parasite Immunology},
year = {2025},
doi = {10.1111/pim.70024}
}
EUVIMED